What is Zacks Research's Forecast for GSK Q1 Earnings?

Key Points

• Zacks Research has increased its Q1 2026 earnings per share estimate for GSK to $1.15, up from a previous estimate of $1.11.
• GSK reported $1.23 earnings per share for its last quarter, surpassing the consensus estimate of $1.12, with revenue hitting $10.64 billion.
• The company recently declared a quarterly dividend of $0.4206, reflecting an annualized yield of 4.3%, with a payout ratio of 77.78%.

GSK PLC Sponsored ADR (NYSE:GSK - Free Report) - Research analysts at Zacks Research increased their Q1 2026 earnings per share estimates for shares of GSK in a report released on Tuesday, September 2nd. Zacks Research analyst Team now anticipates that the pharmaceutical company will post earnings per share of $1.15 for the quarter, up from their prior forecast of $1.11. The consensus estimate for GSK's current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK's Q1 2027 earnings at $1.18 EPS and Q2 2027 earnings at $1.22 EPS.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.

Other equities analysts also recently issued reports about the company. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average target price of $37.38.

GSK Price Performance

NYSE GSK opened at $39.36 on Thursday. The company has a market capitalization of $80.17 billion, a PE ratio of 18.22, a price-to-earnings-growth ratio of 1.72 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The business's fifty day moving average is $38.46 and its 200 day moving average is $38.28. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $44.26.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a $0.4206 dividend. This represents a $1.68 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is presently 77.78%.

Institutional Investors Weigh In On GSK

Several large investors have recently made changes to their positions in GSK. Brighton Jones LLC bought a new stake in shares of GSK in the fourth quarter worth about $528,000. BNP Paribas Financial Markets bought a new stake in GSK during the fourth quarter worth approximately $12,423,000. Bayesian Capital Management LP bought a new position in shares of GSK during the fourth quarter valued at approximately $475,000. Cary Street Partners Financial LLC bought a new position in shares of GSK during the fourth quarter valued at approximately $228,000. Finally, Crestline Management LP bought a new position in shares of GSK during the fourth quarter valued at approximately $1,047,000. 15.74% of the stock is owned by institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.